4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

Core Insights - 4D Molecular Therapeutics announced the presentation of initial interim 52-week data from the Phase 2b Population Extension cohort of the PRISM clinical trial for 4D-150, targeting wet age-related macular degeneration (wet AMD) [1][4] - The presentation will take place at the Angiogenesis, Exudation, and Degeneration 2025 conference on February 8, 2025, with a subsequent webcast on February 10, 2025, to discuss the interim data and analyses [1][3] Presentation Details - The presentation titled "Phase 2b Population Extension Cohort Evaluating 4D-150 in Neovascular Age-Related Macular Degeneration: 52-Week Results" will be delivered by Dr. Dante Pieramici on February 8, 2025, from 2:20 to 2:30 p.m. ET [2] - The webcast on February 10, 2025, at 8:00 a.m. ET will include discussions on the 52-week interim efficacy data for 3E10 vg/eye and long-term safety data from the PRISM trial [3] Product Information - 4D-150 is designed for multi-year sustained delivery of anti-VEGF therapies through a single intravitreal injection, aiming to alleviate the burden of frequent injections for patients with wet AMD and diabetic macular edema (DME) [4][5] - The product utilizes a proprietary vector, R100, developed through the company's Therapeutic Vector Evolution platform [4][6] Company Overview - 4D Molecular Therapeutics is a late-stage biotechnology company focused on genetic medicines for large market diseases, particularly in ophthalmology and pulmonology [6] - The company’s lead program, 4D-150, aims to provide innovative treatment options for millions affected by wet AMD and DME [5][6]